Tina Wenz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tina Wenz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Annette Hofer
Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Zülpicher Str. 47A, Cologne 50674, Germany
4 shared publicationsChristin Tischner
Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Zülpicher Str. 47A, 50674 Cologne, Germany
3 shared publicationsNatalie Noe
Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD) , University of Cologne , Zülpicher Str. 47A, 50674 Cologne , Germany
2 shared publicationsVeronika Lellek
Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD) , University of Cologne , Zülpicher Str. 47A, 50674 Cologne , Germany
2 shared publicationsA. Di Domenico
Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Zülpicher Str. 47A, 50674 Cologne, Germany
1 shared publicationA. Hofer
Institute for Genetics and Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Zülpicher Str. 47A, 50674 Cologne, Germany
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, 32-49
Keep the fire burning: Current avenues in the quest of treating mitochondrial disorders
- 1 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, 32-49
Keep the fire burning: Current avenues in the quest of treating mitochondrial disorders
- Open Access
- 30 December 2014
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (8) , 2247-2266
MTO1 mediates tissue specificity of OXPHOS defects via tRNA modification and translation optimization, which can be bypassed by dietary intervention
Mitochondrial diseases often exhibit tissue-specific pathologies, but this phenomenon is poorly understood. Here we present regulation of mitochondrial translation by the Mitochondrial Translation Optimization Factor 1, MTO1, as a novel player in this scenario. We demonstrate that MTO1 mediates tRNA modification and controls mitochondrial translation rate in a highly tissue-specific manner associated with tissue-specific OXPHOS defects. Activation of mitochondrial proteases, aberrant translation products, as well as defects in OXPHOS complex assembly observed in MTO1 deficient mice further imply that MTO1 impacts translation fidelity. In our mouse model, MTO1-related OXPHOS deficiency can be bypassed by feeding a ketogenic diet. This therapeutic intervention is independent of the MTO1-mediated tRNA modification and involves balancing of mitochondrial and cellular secondary stress responses. Our results thereby establish mammalian MTO1 as a novel factor in the tissue-specific regulation of OXPHOS and fine tuning of mitochondrial translation accuracy.
- 30 December 2014
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (8) , 2247-2266
Open AccessMTO1 mediates tissue specificity of OXPHOS defects via tRNA modification and translation optimization, which can be bypassed by dietary intervention
Mitochondrial diseases often exhibit tissue-specific pathologies, but this phenomenon is poorly understood. Here we present regulation of mitochondrial translation by the Mitochondrial Translation Optimization Factor 1, MTO1, as a novel player in this scenario. We demonstrate that MTO1 mediates tRNA modification and controls mitochondrial translation rate in a highly tissue-specific manner associated with tissue-specific OXPHOS defects. Activation of mitochondrial proteases, aberrant translation products, as well as defects in OXPHOS complex assembly observed in MTO1 deficient mice further imply that MTO1 impacts translation fidelity. In our mouse model, MTO1-related OXPHOS deficiency can be bypassed by feeding a ketogenic diet. This therapeutic intervention is independent of the MTO1-mediated tRNA modification and involves balancing of mitochondrial and cellular secondary stress responses. Our results thereby establish mammalian MTO1 as a novel factor in the tissue-specific regulation of OXPHOS and fine tuning of mitochondrial translation accuracy.
- Retracted
- 15 November 2014
- Published by Wiley in IUBMB Life
- Vol. 66 (11) , 793-802
Retracted: Mitochondrial protein acetylation mediates nutrient sensing of mitochondrial protein synthesis and mitonuclear protein balance
The above article, published online on November 15, 2014 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editors‐in‐Chief, Angelo Azzi and William J. Whelan, Corresponding Author Tina Wenz, the University of Cologne, and Wiley Periodicals, Inc. The article has been retracted on request of the University of Cologne that, after an investigation, established that the data reported in it are not reproducible.Note from the Corresponding Author: “The paper reports on the influence of mitochondrial acetylation on protein synthesis. After publication, several irregularities appeared and have been thoroughly investigated by the lab of the Corresponding Author in cooperation with the commission of Research integrity of the University of Cologne. Both came to the conclusion that data used for the publication are erroneous and that the presented data are not reproducible by the lab of the Corresponding Author and other labs. The Corresponding Author takes responsibility and regrets not having detected these issues before publication. The appropriate corrective action is retraction of the paper. The Corresponding Author apologizes to the scientific community.”Reference: Antonella Di Domenico , Annette Hofer , Federica Tundo , Tina Wenz (2014), , IUBMB Life. 66: 793–802, 2014. DOI: 10.1002/iub.1328
- 15 November 2014
- Published by Wiley in IUBMB Life
- Vol. 66 (11) , 793-802
RetractedRetracted: Mitochondrial protein acetylation mediates nutrient sensing of mitochondrial protein synthesis and mitonuclear protein balance
The above article, published online on November 15, 2014 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editors‐in‐Chief, Angelo Azzi and William J. Whelan, Corresponding Author Tina Wenz, the University of Cologne, and Wiley Periodicals, Inc. The article has been retracted on request of the University of Cologne that, after an investigation, established that the data reported in it are not reproducible.Note from the Corresponding Author: “The paper reports on the influence of mitochondrial acetylation on protein synthesis. After publication, several irregularities appeared and have been thoroughly investigated by the lab of the Corresponding Author in cooperation with the commission of Research integrity of the University of Cologne. Both came to the conclusion that data used for the publication are erroneous and that the presented data are not reproducible by the lab of the Corresponding Author and other labs. The Corresponding Author takes responsibility and regrets not having detected these issues before publication. The appropriate corrective action is retraction of the paper. The Corresponding Author apologizes to the scientific community.”Reference: Antonella Di Domenico , Annette Hofer , Federica Tundo , Tina Wenz (2014), , IUBMB Life. 66: 793–802, 2014. DOI: 10.1002/iub.1328
- 1 August 2014
- Published by Elsevier in Experimental Gerontology
- Vol. 56, 202-220
Post-translational modification of mitochondria as a novel mode of regulation
- 1 August 2014
- Published by Elsevier in Experimental Gerontology
- Vol. 56, 202-220
Post-translational modification of mitochondria as a novel mode of regulation
- Open Access
- 13 December 2013
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (9) , 2400-2415
Defining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo
Previous studies have demonstrated a therapeutic benefit of pharmaceutical PGC-1α activation in cellular and murine model of disorders linked to mitochondrial dysfunction. While in some cases, this effect seems to be clearly associated with boosting of mitochondrial function, additional alterations as well as tissue- and cell-type-specific effects might play an important role. We initiated a comprehensive analysis of the effects of potential PGC-1α-activating drugs and pharmaceutically targeted the PPAR (bezafibrate, rosiglitazone), AMPK (AICAR, metformin) and Sirt1 (resveratrol) pathways in HeLa cells, neuronal cells and PGC-1α-deficient MEFs to get insight into cell type specificity and PGC-1α dependence of their working action. We used bezafibrate as a model drug to assess the effect on a tissue-specific level in a murine model. Not all analyzed drugs activate the PGC pathway or alter mitochondrial protein levels. However, they all affect supramolecular assembly of OXPHOS complexes and OXPHOS protein stability. In addition, a clear drug- and cell-type-specific influence on several cellular stress pathways as well as on post-translational modifications could be demonstrated, which might be relevant to fully understand the action of the analyzed drugs in the disease state. Importantly, the effect on the activation of mitochondrial biogenesis and stress response program upon drug treatment is PGC-1α dependent in MEFs demonstrating not only the pleiotropic effects of this molecule but points also to the working mechanism of the analyzed drugs. The definition of the action spectrum of the different drugs forms the basis for a defect-specific compensation strategy and a future personalized therapeutic approach.
- 13 December 2013
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (9) , 2400-2415
Open AccessDefining the action spectrum of potential PGC-1α activators on a mitochondrial and cellular level in vivo
Previous studies have demonstrated a therapeutic benefit of pharmaceutical PGC-1α activation in cellular and murine model of disorders linked to mitochondrial dysfunction. While in some cases, this effect seems to be clearly associated with boosting of mitochondrial function, additional alterations as well as tissue- and cell-type-specific effects might play an important role. We initiated a comprehensive analysis of the effects of potential PGC-1α-activating drugs and pharmaceutically targeted the PPAR (bezafibrate, rosiglitazone), AMPK (AICAR, metformin) and Sirt1 (resveratrol) pathways in HeLa cells, neuronal cells and PGC-1α-deficient MEFs to get insight into cell type specificity and PGC-1α dependence of their working action. We used bezafibrate as a model drug to assess the effect on a tissue-specific level in a murine model. Not all analyzed drugs activate the PGC pathway or alter mitochondrial protein levels. However, they all affect supramolecular assembly of OXPHOS complexes and OXPHOS protein stability. In addition, a clear drug- and cell-type-specific influence on several cellular stress pathways as well as on post-translational modifications could be demonstrated, which might be relevant to fully understand the action of the analyzed drugs in the disease state. Importantly, the effect on the activation of mitochondrial biogenesis and stress response program upon drug treatment is PGC-1α dependent in MEFs demonstrating not only the pleiotropic effects of this molecule but points also to the working mechanism of the analyzed drugs. The definition of the action spectrum of the different drugs forms the basis for a defect-specific compensation strategy and a future personalized therapeutic approach.
- Retracted
- 1 September 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (5) , 417-426
RETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy
- 1 September 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (5) , 417-426
RetractedRETRACTED: Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy
- 1 March 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (2) , 134-142
Regulation of mitochondrial biogenesis and PGC-1α under cellular stress
- 1 March 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (2) , 134-142
Regulation of mitochondrial biogenesis and PGC-1α under cellular stress
- 9 August 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1817, S118
Sirt3 affects the function and stability of OXPHOS complexes in response to metabolic challenges
- 9 August 2012
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1817, S118
Sirt3 affects the function and stability of OXPHOS complexes in response to metabolic challenges
- Open Access
- 1 January 2011
- Published by Wiley in Journal of Aging Research
- Vol. 2011, 1-12
Mitochondria and PGC-1α in Aging and Age-Associated Diseases
Aging is the most significant risk factor for a range of degenerative disease such as cardiovascular, neurodegenerative and metabolic disorders. While the cause of aging and its associated diseases is multifactorial, mitochondrial dysfunction has been implicated in the aging process and the onset and progression of age-associated disorders. Recent studies indicate that maintenance of mitochondrial function is beneficial in the prevention or delay of age-associated diseases. A central molecule seems to be the peroxisome proliferator-activated receptor γ coactivator α (PGC-1α), which is the key regulator of mitochondrial biogenesis. Besides regulating mitochondrial function, PGC-1α targets several other cellular processes and thereby influences cell fate on multiple levels. This paper discusses how mitochondrial function and PGC-1α are affected in age-associated diseases and how modulation of PGC-1α might offer a therapeutic potential for age-related pathology.
- 1 January 2011
- Published by Wiley in Journal of Aging Research
- Vol. 2011, 1-12
Open AccessMitochondria and PGC-1α in Aging and Age-Associated Diseases
Aging is the most significant risk factor for a range of degenerative disease such as cardiovascular, neurodegenerative and metabolic disorders. While the cause of aging and its associated diseases is multifactorial, mitochondrial dysfunction has been implicated in the aging process and the onset and progression of age-associated disorders. Recent studies indicate that maintenance of mitochondrial function is beneficial in the prevention or delay of age-associated diseases. A central molecule seems to be the peroxisome proliferator-activated receptor γ coactivator α (PGC-1α), which is the key regulator of mitochondrial biogenesis. Besides regulating mitochondrial function, PGC-1α targets several other cellular processes and thereby influences cell fate on multiple levels. This paper discusses how mitochondrial function and PGC-1α are affected in age-associated diseases and how modulation of PGC-1α might offer a therapeutic potential for age-related pathology.